GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more
GRI Bio Inc. (GRI) - Total Liabilities
Latest total liabilities as of December 2025: $2.66 Million USD
Based on the latest financial reports, GRI Bio Inc. (GRI) has total liabilities worth $2.66 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GRI Bio Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how GRI Bio Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GRI Bio Inc. Competitors by Total Liabilities
The table below lists competitors of GRI Bio Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BAB Inc
OTCQB:BABB
|
USA | $1.45 Million |
|
Genetic Technologies Ltd
NASDAQ:GENE
|
USA | $4.36 Million |
|
Ladangbaja Murni PT Tbk
JK:LABA
|
Indonesia | Rp31.52 Billion |
|
Vina San Pedro
SN:VSPT
|
Chile | CL$159.71 Billion |
|
HOV Services Limited
NSE:HOVS
|
India | ₹154.74 Million |
|
Bion Environmental Technologies Inc
OTCQB:BNET
|
USA | $5.96 Million |
|
CanAsia Energy Corp.
PINK:CECAF
|
USA | $6.64 Million |
|
PeterLabs Holdings Bhd
KLSE:0171
|
Malaysia | RM21.70 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down GRI Bio Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GRI Bio Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GRI Bio Inc. (2018–2025)
The table below shows the annual total liabilities of GRI Bio Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.66 Million | +55.71% |
| 2024-12-31 | $1.71 Million | -36.71% |
| 2023-12-31 | $2.70 Million | +34.31% |
| 2022-12-31 | $2.01 Million | -59.37% |
| 2021-12-31 | $4.94 Million | +105.15% |
| 2020-12-31 | $2.41 Million | +126.87% |
| 2019-12-31 | $1.06 Million | +118.36% |
| 2018-12-31 | $486.29K | -- |